| Product Dating |
McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days |
| Features and Benefits |
- Activase® (alteplase) is indicated for the treatment of acute ischemic stroke (AIS)
- Activase® is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and reduction of the incidence of heart failure
- Activase® is indicated for the lysis of acute massive pulmonary embolism (PE)
- Using a large bore needle (e.g., 18 gauge) and a syringe, reconstitute by adding the contents of the accompanying 50 mL vial of SWFI to the 50 mg vial of Activase, directing the SWFI stream into the lyophilized cake
|
- Produced by recombinant DNA technology, Cathflo* is a fibrin-specific t-PA
- Cathflo* is indicated for the restoration of function to central venous access devices (CVADs), as assessed by the ability to withdraw blood
|
- Activase is a tissue plasminogen activator (tPA) indicated for the treatment of Acute Ischemic Stroke (AIS), Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure or Acute Massive Pulmonary Embolism (PE) for lysis
- Activase is proven to reduce disability in patients treated within 3 hours of symptom onset
- Each 100 mg Activase vial (58 million IU) is packaged with diluent for reconstitution (100 mL Sterile Water for Injection, USP), and one transfer device
|
|
- For Use in Central Venous Access Devices
|
